Corrigendum to "Novel clinical phenotypes, drug categorization, and outcome prediction in drug-induced cholestasis: Analysis of a database of 432 patients developed by literature review and machine learning support" [Biomed. Pharmacother. 174 (2024) 116530]

Affiliations

• ¹ Joint Research Unit in Experimental Hepatology, Dep. Biochemistry and Molecular Biology, University of Valencia, Health Research Institute Hospital La Fe & CIBER of Hepatic and Digestive Diseases, Spain. Electronic address: marta.moreno.torres@uv.es.
• ² Joint Research Unit in Experimental Hepatology, Dep. Biochemistry and Molecular Biology, University of Valencia, Health Research Institute Hospital La Fe & CIBER of Hepatic and Digestive Diseases, Spain.
• ³ Health and Biomedicine, LEITAT Technological Center, Barcelona, Spain.
• ⁴ Entity of In Vitro Toxicology and Dermato-Cosmetology, Department of Pharmaceutical and Pharmacological Sciences, Vrije Universiteit Brussel, Belgium.
• ⁵ Department of Chemical Toxicology, Norwegian Institute of Public Health, Oslo, Norway.
• ⁶ ToxTrack, Baltimore, MD, USA.
• ⁷ ProtoQSAR S.L., CEEI-Technology Park of Valencia, Paterna 46980, Spain.
• ⁸ Bayer AG, Machine Learning Research, Research & Development, Pharmaceuticals, Berlin 13353, Germany.
• ⁹ Laboratory of Environmental Toxicology and Chemistry, Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCSS, Milano 20156, Italy.
• ¹⁰ Joint Research Unit in Experimental Hepatology, Dep. Biochemistry and Molecular Biology, University of Valencia, Health Research Institute Hospital La Fe & CIBER of Hepatic and Digestive Diseases, Spain. Electronic address: ramiro.jover@uv.es.